PMS-PIROXICAM SUPPOSITORIES -20MG SUPPOSITORY

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

PIROXICAM

Доступна з:

PHARMASCIENCE INC

Код атс:

M01AC01

ІПН (Міжнародна Ім'я):

PIROXICAM

Дозування:

20MG

Фармацевтична форма:

SUPPOSITORY

Склад:

PIROXICAM 20MG

Адміністрація маршрут:

RECTAL

Одиниць в упаковці:

30 SUPPOSITORIES

Тип рецепту:

Prescription

Терапевтична области:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Огляд продуктів:

Active ingredient group (AIG) number: 0114612001; AHFS:

Статус Авторизація:

CANCELLED POST MARKET

Дата Авторизація:

2016-10-28

Характеристики продукта

PRODUCT MONOGRAPH
Pr
pms-PIROXICAM
Piroxicam, USP
10 mg and 20 mg Capsules
10 mg and 20 mg Suppositories
Nonsteroidal Anti-Inflammatory Drug (NSAID)
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Avenue
February 17, 2010
Montreal, Quebec
H4P 2T4
CONTROL # 131400
_ _
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT INFORMATION
.......................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................5
ADVERSE
REACTIONS..................................................................................................14
DRUG INTERACTIONS
.................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................22
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL
PHARMACOLOGY.............................................................23
STORAGE AND
STABILITY..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................24
PART II: SCIENTIFIC INFORMATION
................................................................................26
PHARMACEUTICAL
INFORMATION..........................................................................26
CLINICAL TRIALS
..........................................................................................................27
DETAILED PHARMACOLOGY
.....................................................................................27